

GyneLotrimin advertisement.

[s.l.]: [s.n.], 1975

<https://digital.library.wisc.edu/1711.dl/JSTTOR4AZESUM9E>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.

CANDIDA ALBICANS

an opportunistic organism
in susceptible patients¹

with tight
clothing

in
pregnancy

on "the pill"

in
obesity



an effective treatment for vulvovaginal candidiasis

Gyne-Lotrimin®

one
a
day for **7**
days

brand of clotrimazole
Vaginal Tablets  100 mg.

usually reduces
Candida albicans to
remnants of lysed cells
within 12 hours²

High-Risk Patients

Frequent inhabitant of the human vagina, *Candida albicans* is opportunistic in susceptible patients, growing into yellow-white plaques on the vaginal mucosa, *i.e.*, vaginal candidiasis. The women at risk include those who are:¹

- ☐ pregnant
- ☐ using oral contraceptives
- ☐ obese
- ☐ wearers of tight clothing — especially synthetic fabrics
- ☐ using antibiotic/immunosuppressive medication
- ☐ diabetic

Clinical Action

GYNE-LOTRIMIN usually cures vulvovaginal candidiasis in half the time of the conventional 14-day courses of therapy — in only 7 days. *GYNE-LOTRIMIN is so effective, it has been shown to separate the cell body from the cell wall in budding yeast cells, reducing *Candida albicans* to remnants of lysed cells usually within 12 hours.²* The 7-day course of therapy is necessary to prevent candidal cells in deeper layers from proliferating. The therapeutic regimen is so short, few patients will “drop out,” adding to success rates.

GYNE-LOTRIMIN has been safely used in pregnancy during the latter two trimesters. Tablets dissolve rapidly, without stain or odor. It is well tolerated, with only 1.6% of 689 patients treated reporting minor complaints (e.g., mild burning).

References:

1. When vaginitis keeps coming back. *Patient Care* 8:44-77, Sept 15, 1974.
2. Voigt WH, Schnell JD: Electron-microscopic studies on human-pathogenic fungi. Communication II: Ultrastructural changes in *Candida albicans* cells in the human vaginal epithelium during treatment with clotrimazole. *Arzneim Forsch (Drug Research)* 24:516-521, 1974.



Gyne-Lotrimin[®]

one
a day
for
7
days

brand of clotrimazole
Vaginal Tablets 100 mg.

**7 h.s. doses can usually
cure her while she sleeps**

GYNE-LOTRIMIN[®]
brand of clotrimazole
Vaginal Tablets

CONTRAINDICATIONS: GYNE-LOTRIMIN Vaginal Tablets are contraindicated in women who have shown hypersensitivity to this drug.

PRECAUTIONS: Laboratory Tests: If there is a lack of response to GYNE-LOTRIMIN, appropriate microbiological studies should be repeated to confirm the diagnosis and rule out other pathogens.

Usage in Pregnancy: While GYNE-LOTRIMIN Vaginal Tablets have not been studied in the first trimester of pregnancy, use in the second and third trimesters has not been associated with ill effects. Follow-up reports now available on 41 neonates of 107 pregnant patients reveal no adverse effects or complications attributable to GYNE-LOTRIMIN therapy.

Application of ¹⁴C-labeled clotrimazole has shown negligible absorption (peak of

0.03 mcg/ml of serum 24 hours after insertion of a 100 mg. Tablet) from both normal and inflamed human vaginal mucosa.

ADVERSE REACTIONS: Eleven (1.6%) of 689 patients treated with GYNE-LOTRIMIN reported complaints during therapy that were possibly drug-related. Mild burning occurred in four patients while other complaints, such as skin rash, lower abdominal cramps, slight urinary frequency, and burning or irritation in the sexual partner, occurred rarely. In no case was it necessary to discontinue treatment with GYNE-LOTRIMIN brand of clotrimazole.

Do not store above 35°C (95°F).

FEBRUARY 1976

11059104

Supplied as a foil strip of 7 tablets
with a plastic applicator and patient
instructions.

For more complete details, consult package insert or Delbay literature available from your Schering Representative or Professional Services Department, Delbay Pharmaceuticals, Inc., Kenilworth, N.J. 07033.



Distributed by
Delbay Pharmaceuticals, Inc.

Manufactured by **Schering Corporation**
Kenilworth, New Jersey 07033

DEL-7070